19 Oct 2023 , 03:11 PM
Granules India Ltd has received approval from the US Food & Drug Administration (USFDA) for its generic Esomeprazole Magnesium delayed-release capsules. The approved capsules come in strengths of 20 mg and 40 mg and are indicated for the short-term treatment of heartburn and other symptoms associated with gastroesophageal reflux disease (GERD).
These capsules are bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Nexium Delayed-Release Capsules, 20 mg and 40 mg, produced by AstraZeneca Pharmaceuticals LP.
In addition to heartburn, Esomeprazole Magnesium capsules are also prescribed for risk reduction of nonsteroidal anti-inflammatory drugs (NSAID)-associated gastric ulcer in adults and long-term treatment of pathological hypersecretory conditions, including Zollinger-Ellison syndrome.
The annual US market for Esomeprazole Magnesium delayed-release capsules is estimated to be around USD 168 million, as per IQVIA/IMS Health data from July 2023.
For feedback and suggestions, write to us at editorial@iifl.com
Related Tags
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.